Tumor Budding in Colorectal Cancer: Biological Basis, Clinical Risk Stratification, and Digital Pathology
Cancers · 29.10.2026 · 18 (21) · 3493
DOI: 10.3390/cancers18213493 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.10.2026. Verfasst von Enrique Bernal-Morell und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital General Universitario Reina Sofía, 30003 Murcia, Spain. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tumor budding, defined as single tumor cells or clusters of up to four cells at the invasive front, is a morphological marker of tumor-cell dissociation and stromal invasion in colorectal cancer. Standardization by the International Tumor Budding Consensus Conference (ITBCC) established a reproducible hematoxylin-and-eosin-based method and enabled broader incorporation of budding into pathology reporting and clinical risk assessment. Intermediate- and high-grade budding are associated with lymph node metastasis in pT1 colorectal cancer, while high-grade budding identifies a subgroup of stage II colon cancers with increased recurrence risk. Adverse prognostic associations have also been reported in stage III disease and in rectal cancer after neoadjuvant therapy, although evidence that budding predicts benefit from a specific treatment is still insufficient. At the biological level, budding is linked to partial epithelial–mesenchymal transition, altered cell adhesion, cytoskeletal remodeling, and interactions with fibroblasts, extracellular matrix, and immune cells. Digital pathology and artificial intelligence may improve hotspot selection, quantification, and spatial characterization, but their clinical use depends on external validation, control of domain shift, and continued pathologist oversight. Tumor budding is therefore best interpreted as a complementary morphological biomarker alongside TNM stage, established histopathological risk factors, molecular features, and clinical context.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Hospital General Universitario Reina Sofía, 30003 Murcia, Spain.
- Department of Medicine, Faculty of Medicine, University of Murcia, 30120 El Palmar, Spain.
- Department of Pathology, Hospital General Universitario Reina Sofía, 30003 Murcia, Spain.
- Department of Ophthalmology, Optometry, Otolaryngology and Pathology, Faculty of Medicine, University of Murcia, 30120 El Palmar, Spain.
ORCID-Profile: Francisco Martínez-Díaz, Francisco García-Molina
Zitieren
APA
Bernal-Morell, E., Martínez-Díaz, F., & García-Molina, F. (2026). Tumor Budding in Colorectal Cancer: Biological Basis, Clinical Risk Stratification, and Digital Pathology. Cancers, 18(21), 3493. https://doi.org/10.3390/cancers18213493
Vancouver
Bernal-Morell E, Martínez-Díaz F, García-Molina F. Tumor Budding in Colorectal Cancer: Biological Basis, Clinical Risk Stratification, and Digital Pathology. Cancers. 2026;18(21):3493. doi:10.3390/cancers18213493
BibTeX
@article{BernalMorell2026,
author = {Bernal-Morell, Enrique and Martínez-Díaz, Francisco and García-Molina, Francisco},
title = {Tumor Budding in Colorectal Cancer: Biological Basis, Clinical Risk Stratification, and Digital Pathology},
journal = {Cancers},
year = {2026},
volume = {18},
number = {21},
pages = {3493},
doi = {10.3390/cancers18213493}
}
EUVIMED